Back to
CAPTRUST FINANCIAL ADVISORS
AIMT3 quarters
Position history for
CAPTRUST FINANCIAL ADVISORS's holdings in AIMMUNE THERAPEUTICS INC
As of its Q3 2020 13F, Captrust held 100 shares of AIMT (Aimmune Therapeutics), worth $3,000. Captrust's 13F filings listed AIMT from Q2 2020 to Q3 2020, 2 quarterly filings.
Final Value
$0
Final Shares
0
Total Value Change
-$4,000
Total Shares Change
-265
Quarter-by-Quarter History
Other major holders of AIMT: PRICE T ROWE ASSOCIATES INC /MD/, FMR LLC, Pentwater Capital Management LP